Workstation Ergonomics Program at Al-Baha University (ERG-ABU)

July 6, 2026 updated by: Dr. Wael Alghamdi, Al-Baha University

Workstation Ergonomics Intervention to Reduce Musculoskeletal Symptoms Among University Employees

This study evaluates a workstation ergonomics program at Al-Baha University aimed at reducing work-related musculoskeletal symptoms among university employees who use computers regularly. The program includes an ergonomics self-assessment of the workstation, individualized guidance on proper workstation setup and posture, and practical recommendations to improve daily work habits. Participants will be followed for approximately four weeks, and changes in musculoskeletal symptoms and related outcomes will be assessed before and after the program, compared with a usual-practice control group.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

This was a four-week, two-arm, parallel-group, open-label randomized controlled trial conducted among university employees at Al-Baha University. Eligible participants were randomized to either a workstation ergonomics intervention group or a usual-practice control group. Assessments were conducted at baseline and at the 4-week follow-up. The intervention consisted of a structured workstation ergonomics package including a computer workstation self-assessment checklist, individualized feedback and practical recommendations to optimize workstation arrangement and working posture, and brief reminders to support adherence during the follow-up period. The primary objective was to evaluate whether the ergonomics program reduced musculoskeletal symptom burden compared with usual practice in a real-world university workplace setting.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
150

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Saudi Arabia
      • Al Bahah, Saudi Arabia, 59865
        • Al-Baha University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Adults aged 18-55 years.
  • Affiliated with Al-Baha University (staff, or faculty) and regularly use a computer workstation (≥3 hours/day or ≥15 hours/week).
  • Able to read and complete the online questionnaire and provide informed consent.

Exclusion Criteria:

  • Current severe musculoskeletal disorder or recent major injury/surgery that markedly limits daily activities or requires ongoing medical treatment.
  • Diagnosed neurological or rheumatologic condition affecting the musculoskeletal system (e.g., severe radiculopathy, inflammatory arthritis).
  • Pregnancy (if you prefer to exclude it).
  • Participation in another ergonomics intervention program during the study period.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Ergonomics Program (Intervention)
Participants will receive an office-workstation ergonomics program including a self-assessment checklist-based evaluation and tailored recommendations for workstation adjustment and safe working posture, along with brief educational guidance and periodic follow-up reminders during the study period.
Behavioral: Workstation Ergonomics Program
Participants in the intervention arm will complete an online computer workstation self-assessment checklist. Based on their responses, they will receive individualized workstation ergonomics guidance and educational materials covering optimal sitting posture and workstation setup (chair/desk height, monitor position, keyboard/mouse placement, and lighting), as well as recommendations for regular micro-breaks and simple stretching. Guidance will be delivered electronically after baseline assessment, and participants will be encouraged to implement the recommendations throughout the follow-up period (4 weeks) with reinforcement reminders.
Other Names:
  • Ergonomics Education and Workstation Self-Assessment
Active Comparator: Usual Practice (Control)
Participants will continue their usual workstation practices during the study period and will not receive the ergonomics recommendations/education until after completion of follow-up assessment.
Behavioral: Usual Practice (Control)
Participants in the control arm will receive no ergonomics training, individualized recommendations, or educational materials during the study period and will continue their usual computer workstation practices. After completion of follow-up assessments, the control group will be offered the same ergonomics educational materials and general workstation guidance provided to the intervention arm.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Change in number of painful body regions
Time Frame: Baseline and 4 weeks.
Change from baseline to the 4-week follow-up in musculoskeletal symptom burden, operationalized as the number of body regions with self-reported musculoskeletal pain or symptoms during the previous 7 days, assessed using the Nordic Musculoskeletal Questionnaire (NMQ). Higher values indicate a greater musculoskeletal symptom burden. Outcomes will be compared between the intervention and control arms.
Baseline and 4 weeks.

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Change in workstation ergonomic quality score
Time Frame: Baseline and 4 weeks
Change from baseline to the 4-week follow-up in workstation ergonomic quality, measured using a structured computer workstation ergonomics self-assessment checklist. Higher scores indicate better workstation ergonomic quality. Outcomes will be compared between the intervention and control arms.
Baseline and 4 weeks
Change in total musculoskeletal pain severity score
Time Frame: Baseline and 4 weeks
Change from baseline to the 4-week follow-up in total musculoskeletal pain severity, calculated by summing pain severity ratings across assessed body regions. Higher scores indicate greater overall pain severity. Outcomes will be compared between the intervention and control arms.
Baseline and 4 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Al-Baha University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
February 10, 2026

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
February 10, 2026

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
April 10, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
January 27, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
January 27, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
February 2, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
July 8, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 6, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
July 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 46120176/2025

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings